Immunologic and toxicologic study of disaccharide tripeptide glycerol dipalmitoyl: a new lipophilic immunomodulator |
| |
| Authors: | G J Vosika D A Cornelius J A Bennek J R Sadlik C W Gilbert |
| |
| Affiliation: | ImmunoTherapeutics, Inc., Fargo, ND 58102. |
| |
| Abstract: | A new lipophilic immunomodulator, disaccharide tripeptide glycerol dipalmitoyl (DTP-GDP), has been synthesized and evaluated for its immunologic activity and toxicology. DTP-GDP alone or in liposomes is more effective as an adjuvant and in activating macrophages compared with muramyldipeptide (MDP). Preclinical studies demonstrate no evidence of toxicity, including vasculitis. DTP-GDP in liposomes has shown antitumor activity in phase I clinical trials. |
| |
| Keywords: | |
|
|
